330 related articles for article (PubMed ID: 17121020)
1. [Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer].
Sun CC; Zheng W; Kong CZ; Wang X; Yang CM
Zhonghua Nan Ke Xue; 2006 Oct; 12(10):904-5, 909. PubMed ID: 17121020
[TBL] [Abstract][Full Text] [Related]
2. The chromogranin-A (CgA) in prostate cancer.
Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334
[TBL] [Abstract][Full Text] [Related]
4. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
Sciarra A; Gentile V; Monti S; Dattilo C; Autran Gomez A; Salciccia S; Pannunzi LP; Toscano V; Di Silverio F
Urol Int; 2008; 80(1):68-73. PubMed ID: 18204237
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
[TBL] [Abstract][Full Text] [Related]
6. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
7. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
Leibovitch I; Pinthus Y; Sella BA; Ramon J
Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
[TBL] [Abstract][Full Text] [Related]
8. Correlation between age and Chromogranin A determination in prostate diseases.
Mearini L; Zucchi A; Scarponi E; Nunzi E; Aglietti MC; Bini V; Porena M
Cancer Biomark; 2011-2012; 10(3-4):117-23. PubMed ID: 22674297
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
[TBL] [Abstract][Full Text] [Related]
10. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
11. Serum keratinocyte growth factor measurement in patients with prostate cancer.
Mehta PB; Robson CN; Neal DE; Leung HY
J Urol; 2000 Dec; 164(6):2151-5. PubMed ID: 11061946
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
13. [Established oneself the detection of serum prostate specific antigen and application in clinical practice].
Feng T; Dou CQ; Xia TL
Zhonghua Wai Ke Za Zhi; 1994 Nov; 32(11):685-7. PubMed ID: 7539736
[TBL] [Abstract][Full Text] [Related]
14. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
[TBL] [Abstract][Full Text] [Related]
15. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
Sciarra A; Di Silverio F; Autran AM; Salciccia S; Gentilucci A; Alfarone A; Gentile V
Urol Int; 2009; 82(2):147-51. PubMed ID: 19321999
[TBL] [Abstract][Full Text] [Related]
16. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K
Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818
[TBL] [Abstract][Full Text] [Related]
19. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
20. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
Burgio SL; Conteduca V; Menna C; Carretta E; Rossi L; Bianchi E; Kopf B; Fabbri F; Amadori D; De Giorgi U
Endocr Relat Cancer; 2014 Jun; 21(3):487-93. PubMed ID: 24741024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
